PDCD1 and breast cancer: Given the increasing number of PD-1-focused clinical trials in BC [4,35,36], we sought to evaluate the feasibility of combining IT CPMV with IT anti-PD-1 using an optimal animal model, like dogs with spontaneous mammary tumors, to support the implementation of clinical trials of IT CPMV combined with approved anti-PD-1 in human BC patients.